

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 9/28/1980  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Streptococcus pneumoniae Antibodies, IgG (9 Serotypes)**

ARUP test code 2008919

Pneumo serotype 2 IgG (PNX)	0.45 ug/mL
Pneumo serotype 10A IgG (PNX)	15.87 ug/mL
Pneumo serotype 11A IgG (PNX)	2.77 ug/mL
Pneumo serotype 15B IgG (PNX)	8.93 ug/mL
Pneumo serotype 17F IgG (PNX)	6.80 ug/mL
Pneumo serotype 19A IgG (P13,PNX)	34.22 ug/mL
Pneumo serotype 20 IgG (PNX)	2.18 ug/mL
Pneumo serotype 22F IgG (PNX)	3.11 ug/mL
Pneumo serotype 33F IgG (PNX)	2.35 ug/mL
Pneumo Serotype Interpretation	See Note

**H=High, L=Low, \*=Abnormal, C=Critical**

**INTERPRETIVE INFORMATION: Streptococcus pneumoniae Antibodies, IgG**

A pre- and post-vaccination comparison is required to adequately assess the humoral immune response to Prevnar 7 (P7), Prevnar 13 (P13), and/or Pneumovax 23 (PNX) Streptococcus pneumoniae vaccines. Pre-vaccination samples should be collected prior to vaccine administration. Post-vaccination samples should be obtained at least 4 weeks after immunization. Testing of post-vaccination samples alone will provide only general immune status of the individual to various pneumococcal serotypes.

In the case of pure polysaccharide vaccine, indication of immune system competence is further delineated as an adequate response to at least 50 percent of the serotypes in the vaccine challenge for those 2-5 years of age and to at least 70 percent of the serotypes in the vaccine challenge for those 6-65 years of age. Individual immune response may vary based on age, past exposure, immunocompetence, and pneumococcal serotype.

Responder Status	Antibody Ratio
Non-Responder . . . . .	Less than 2-fold
Weak Responder . . . . .	2-fold to 4-fold
Good Responder . . . . .	Greater than 4-fold

A response to 50-70 percent or more of the serotypes in the vaccine challenge is considered a normal humoral response(1). Antibody concentration greater than 1.0 - 1.3 ug/mL is generally considered long-term protection(2).

References:  
1. Daly TM, Pickering JW, Zhang X, Prince HE, Hill HR. Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements. Clin Vaccine Immunol. 2014;21(7):982-8.  
2. Daly TM, Hill HR. Use and Clinical Interpretation of Pneumococcal Antibody Measurements in the Evaluation of Humoral Immune Function. Clin Vaccine Immunol. 2015;22(2):148-152.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

---

**H=High, L=Low, \*=Abnormal, C=Critical**

---

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Pneumo serotype 2 IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 10A IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 11A IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 15B IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 17F IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 19A IgG (P13,PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 20 IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 22F IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo serotype 33F IgG (PNX)	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pneumo Serotype Interpretation	22-069-126521	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 22-069-126521  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 3 of 3 | Printed: 4/29/2022 11:10:09 AM  
4848